Specific and efficient targeting of adenovirus vectors to macrophages: Application of a fusion protein between an adenovirus-binding fragment and avidin, linked to a biotinylated oligonucleotide

Journal of Gene Medicine

Volumn 8, Issue 6, 2006, Pages 668-678

  Gras, J C Emile ^a   Verkuijlen, Paul ^a   Frants, Rune R ^a   Havekes, Louis M ^a,b   van Berkel, Theo J C ^c   Biessen, Erik A L ^c   van Dijk, K Willems ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adenovirus; Atherosclerosis; Gene therapy; Macrophages; Targeting

Indexed keywords

ADENOVIRUS VECTOR; AVIDIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; HYBRID PROTEIN; LUCIFERASE; OLIGONUCLEOTIDE; SCAVENGER RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOTINYLATION; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; COXSACKIE VIRUS; CULTURE MEDIUM; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MACROPHAGE; MOLECULAR CLONING; MOUSE; NONHUMAN; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; REPORTER GENE; SEROTYPE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; AVIDIN; BIOTINYLATION; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; LIGANDS; MACROPHAGES; MICE; OLIGONUCLEOTIDES; RECEPTORS, VIRUS; RECOMBINANT FUSION PROTEINS;

ADENOVIRIDAE;

EID: 33745278536     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.895     Document Type: Article

References (60)

1. van Dijk KW, Kypreos KE, d'Oliveira C, et al. Adenovirus-mediated gene transfer. Methods Mol Biol 2003; 209: 231-247.
2. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
3. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
4. Svensson U. Role of vesicles during adenovirus 2 internalization into HeLa cells. J Virol 1985; 55: 442-449.
5. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
6. Wickham TJ, Filardo EJ, Cheresh DA, et al. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994; 127: 257-264.
7. Fechner H, Haack A, Wang H, et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999; 6: 1520-1535.
8. Carson SD, Hobbs JT, Tracy SM, et al. Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells: regulation in response to cell density. J Virol 1999; 73: 7077-7079.
9. Kaner RJ, Worgall S, Leopold PL, et al. Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor. Am J Respir Cell Mol Biol 1999; 20: 361-370.
10. Havenga MJ, Lemckert AA, Grimbergen JM, et al. Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 2001; 75: 3335-3342.
11. Knaan-Shanzer S, van der Velde I, Havenga MJ, et al. Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B. Hum Gene Ther 2001; 12: 1989-2005.
12. Rea D, Havenga MJ, van Den AM, et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001; 166: 5236-5244.
13. Ophorst OJ, Kostense S, Goudsmit J, et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004; 22: 3035-3044.
14. Schoggins JW, Gall JG, Falck-Pedersen E. Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo. J Virol 2003; 77: 1039-1048.
15. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
16. Krasnykh V, Dmitriev I, Mikheeva G, et al. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998; 72: 1844-1852.
17. Belousova N, Krendelchtchikova V, Curiel DT, et al. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002; 76: 8621-8631.
18. Wu H, Seki T, Dmitriev I, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 2002; 13: 1647-1653.
19. Nicklin SA, Von Seggern DJ, Work LM, et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-542.
20. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
21. Hidaka C, Milano E, Leopold PL, et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999; 103: 579-587.
22. van Deutekom JC, Cao B, Pruchnic R, et al. Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle. J Gene Med 1999; 1: 393-399.
23. Bouri K, Feero WG, Myerburg MM, et al. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 1999; 10: 1633-1640.
24. Gonzalez R, Vereecque R, Wickham TJ, et al. Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. Hum Gene Ther 1999; 10: 2709-2717.
25. Gonzalez R, Vereecque R, Wickham TJ, et al. Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Gene Ther 1999; 6: 314-320.
26. Yoshida Y, Sadata A, Zhang W, et al. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum Gene Ther 1998; 9: 2503-2515.
27. Parrott MB, Adams KE, Mercier GT, et al. Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol Ther 2003; 8: 688-700.
28. Perlman H, Liu H, Georganas C, et al. Modifications in adenoviral coat fiber proteins and transcriptional regulatory sequences enhance transgene expression. J Rheumatol 2002; 29: 1593-1600.
29. Douglas JT, Rogers BE, Rosenfeld ME, et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-1578.
30. Curiel DT. Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci 1999; 886: 158-171.
31. Pereboev AV, Nagle JM, Shakhmatov MA, et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 2004; 9: 712-720.
32. Krasnykh V, Douglas JT. Targeted adenoviral vectors I: transductional targeting. In Adenoviral Vectors for Gene Therapy, Curiel DT, Douglas JT (eds). Academic Press, Inc.: San Diego, 2002; 205-245.
33. Rogers BE, Douglas JT, Ahlem C, et al. Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther 1997; 4: 1387-1392.
34. Smith JS, Keller JR, Lohrey NC, et al. Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens. Proc Natl Acad Sci U S A 1999; 96: 8855-8860.
35. Campos SK, Parrott MB, Barry MA. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol Ther 2004; 9: 942-954.
36. Kypreos KE, van Dijk KW, van Der ZA, et al. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J Biol Chem 2001; 276: 19778-19786.
37. Fallaux FJ, Bout A, Van Der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9: 1909-1917.
38. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
39. Dickinson J, Fowler SJ. Quantification of proteins on Western blots using ECL. In The Protein Protocols Handbook, Walker JM (ed). Humana Press: Totowa, 2004; 429-438.
40. Bergelson JM, Krithivas A, Celi L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72: 415-419.
41. Gope ML, Keinanen RA, Kristo PA, et al. Molecular cloning of the chicken avidin cDNA. Nucleic Acids Res 1987; 15: 3595-3606.
42. Henry LJ, Xia D, Wilke ME, et al. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J Virol 1994; 68: 5239-5246.
43. Burke B, Sumner S, Maitland N, et al. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J Leukoc Biol 2002; 72: 417-428.
44. Pearson AM. Scavenger receptors in innate immunity. Curr Opin Immunol 1996; 8: 20-28.
45. Biessen EA, Vietsch H, Kuiper J, et al. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol 1998; 53: 262-269.
46. Jakubczak JL, Rollence ML, Stewart DA, et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J Virol 2001; 75: 2972-2981.
47. Laitinen OH, Marttila AT, Airenne KJ, et al. Biotin induces tetramerization of a recombinant monomeric avidin. A model for protein-protein interactions. J Biol Chem 2001; 276: 8219-8224.
48. Houen G, Hansen K. Interference of sugars with the binding of biotin to streptavidin and avidin. J Immunol Methods 1997; 210: 115-123.
49. David A, Kopeckova P, Minko T, et al. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. Eur J Cancer 2004; 40: 148-157.
50. Sliedregt LA, van Rossenberg SM, Autar R, et al. Design and synthesis of a multivalent homing device for targeting to murine CD22. Bioorg Med Chem 2001; 9: 85-97.
51. Maier MA, Yannopoulos CG, Mohamed N, et al. Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting. Bioconjugate Chem 2003; 14: 18-29.
52. van Rossenberg SM, van Keulen AC, Drijfhout JW, et al. Stable polyplexes based on arginine-containing oligopeptides for in vivo gene delivery. Gene Ther 2004; 11: 457-464.
53. Michon IN, Hauer AD, der Thusen JH, et al. Targeting of peptides to restenotic vascular smooth muscle cells using phage display in vitro and in vivo. Biochim Biophys Acta 2002; 1591: 87-97.
54. Biessen EA, Beuting DM, Vietsch H, et al. Specific targeting of the antiviral drug 5-iodo 2′-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine. J Hepatol 1994; 21: 806-815.
55. Molenaar TJ, Appeldoorn CC, de Haas SA, et al. Specific inhibition of P-selectin-mediated cell adhesion by phage display-derived peptide antagonists. Blood 2002; 100: 3570-3577.
56. Dmitriev I, Kashentseva E, Rogers BE, et al. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 2000; 74: 6875-6884.
57. Goldman CK, Rogers BE, Douglas JT, et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997; 57: 1447-1451.
58. Watkins SJ, Mesyanzhinov VV, Kurochkina LP, et al. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther 1997; 4: 1004-1012.
59. Roulon T, Helene C, Escude C. Coupling of a targeting peptide to plasmid DNA using a new type of padlock oligonucleotide. Bioconjugate Chem 2002; 13: 1134-1139.
60. Bijsterbosch MK, Manoharan M, Rump ET, et al. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 1997; 25: 3290-3296.